Skip to main content
PMC home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 1997 Oct;81(10):832–834. doi: 10.1136/bjo.81.10.832

Activated protein C resistance in patients with central retinal vein occlusion

J Larsson 1, A Sellman 1, B Bauer 1
PMCID: PMC1722017  PMID: 9486021

Abstract

AIM/BACKGROUND—A new defect in the anticoagulant system has recently been discovered—activated protein C resistance. The frequency of this disorder has been shown to be increased in young patients (<50 years of age) with central retinal vein occlusion. This study was carried out to determine if there was any overrepresentation of activated protein C resistance in patients >50 years of age with central retinal vein occlusion.
METHODS—Blood samples were obtained from 83 patients >50 years of age and with a history of central retinal vein occlusion. The blood samples were analysed for activated protein C resistance with standard clinical laboratory methods.
RESULTS—In this material 11% of the patients were resistant to activated protein C. The normal incidence of activated protein C resistance in the same geographical area is 10-11%.
CONCLUSION—Activated protein C resistance does not seem to be a cause of central retinal vein occlusion in people older than 50 years.



Full Text

The Full Text of this article is available as a PDF (74.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alhenc-Gelos M., Gandrille S., Aubry M. L., Emmerich J., Flessinger J. N., Aiach M. Unexplained thrombosis and factor V Leiden mutation. Lancet. 1994 Aug 20;344(8921):555–556. doi: 10.1016/s0140-6736(94)91954-2. [DOI] [PubMed] [Google Scholar]
  2. Baker R., Thom J., van Bockxmeer F. Diagnosis of activated protein C resistance (factor V Leiden) Lancet. 1994 Oct 22;344(8930):1162–1162. doi: 10.1016/s0140-6736(94)90672-6. [DOI] [PubMed] [Google Scholar]
  3. Bertina R. M., Koeleman B. P., Koster T., Rosendaal F. R., Dirven R. J., de Ronde H., van der Velden P. A., Reitsma P. H. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994 May 5;369(6475):64–67. doi: 10.1038/369064a0. [DOI] [PubMed] [Google Scholar]
  4. Chan L. C., Bourke C., Lam C. K., Liu H. W., Brookes S., Jenkins V., Pasi J. Lack of activated protein C resistance in healthy Hong Kong Chinese blood donors--correlation with absence of Arg506-Gln mutation of factor V gene. Thromb Haemost. 1996 Mar;75(3):522–523. [PubMed] [Google Scholar]
  5. Dahlbäck B., Carlsson M., Svensson P. J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):1004–1008. doi: 10.1073/pnas.90.3.1004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dahlbäck B., Carlsson M., Svensson P. J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):1004–1008. doi: 10.1073/pnas.90.3.1004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dahlbäck B., Hillarp A., Rosen S., Zöller B. Resistance to activated protein C, the FV:Q506 allele, and venous thrombosis. Ann Hematol. 1996 Apr;72(4):166–176. doi: 10.1007/s002770050157. [DOI] [PubMed] [Google Scholar]
  8. Dahlbäck B. Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene. Haemostasis. 1994 Mar-Apr;24(2):139–151. doi: 10.1159/000217094. [DOI] [PubMed] [Google Scholar]
  9. Dahlbäck B., Svensson P. J. Nyupptckt rubbning i antikoagulationen. Resistens mot aktiverat protein C orsak till trombos. Lakartidningen. 1994 Jan 5;91(1-2):50–53. [PubMed] [Google Scholar]
  10. Denson K. W., Reed S. V., Haddon M. E. The modified APC resistance test. Thromb Haemost. 1995 Sep;74(3):995–995. [PubMed] [Google Scholar]
  11. Freyburger G., Bilhou-Nabera C., Dief S., Javorschi S., Labrouche S., Lerebeller M. J., Boisseau M. R. Technical and biological conditions influencing the functional APC resistance test. Thromb Haemost. 1996 Mar;75(3):460–465. [PubMed] [Google Scholar]
  12. Greengard J. S., Sun X., Xu X., Fernandez J. A., Griffin J. H., Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet. 1994 May 28;343(8909):1361–1362. doi: 10.1016/s0140-6736(94)92497-x. [DOI] [PubMed] [Google Scholar]
  13. Hellgren M., Svensson P. J., Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol. 1995 Jul;173(1):210–213. doi: 10.1016/0002-9378(95)90192-2. [DOI] [PubMed] [Google Scholar]
  14. Holm J., Zöller B., Berntorp E., Erhardt L., Dahlbäck B. Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries. J Intern Med. 1996 Mar;239(3):221–226. doi: 10.1046/j.1365-2796.1996.470808000.x. [DOI] [PubMed] [Google Scholar]
  15. Jeong H., Kim M., Lee J., Hahn S. H., Park S., Yoo O. J. A 5-nucleotide insertion in the antithrombin gene causing a quantitative antithrombin deficiency. Thromb Haemost. 1997 Jan;77(1):212–213. [PubMed] [Google Scholar]
  16. Jorquera J. I., Montoro J. M., Fernández M. A., Aznar J. A., Aznar J. Modified test for activated protein C resistance. Lancet. 1994 Oct 22;344(8930):1162–1163. doi: 10.1016/s0140-6736(94)90673-4. [DOI] [PubMed] [Google Scholar]
  17. Koster T., Rosendaal F. R., de Ronde H., Briët E., Vandenbroucke J. P., Bertina R. M. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993 Dec 18;342(8886-8887):1503–1506. doi: 10.1016/s0140-6736(05)80081-9. [DOI] [PubMed] [Google Scholar]
  18. Larsson J., Olafsdottir E., Bauer B. Activated protein C resistance in young adults with central retinal vein occlusion. Br J Ophthalmol. 1996 Mar;80(3):200–202. doi: 10.1136/bjo.80.3.200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Legnani C., Palareti G., Biagi R., Coccheri S. Activated protein C resistance in deep-vein thrombosis. Lancet. 1994 Feb 26;343(8896):541–542. doi: 10.1016/s0140-6736(94)91494-x. [DOI] [PubMed] [Google Scholar]
  20. Majerus P. W. Human genetics. Bad blood by mutation. Nature. 1994 May 5;369(6475):14–15. doi: 10.1038/369014a0. [DOI] [PubMed] [Google Scholar]
  21. Malm J., Laurell M., Nilsson I. M., Dahlbäck B. Thromboembolic disease--critical evaluation of laboratory investigation. Thromb Haemost. 1992 Jul 6;68(1):7–13. [PubMed] [Google Scholar]
  22. McGrath M. A., Wechsler F., Hunyor A. B., Penny R. Systemic factors contributory to retinal vein occlusion. Arch Intern Med. 1978 Feb;138(2):216–220. [PubMed] [Google Scholar]
  23. Rees D. C., Cox M., Clegg J. B. World distribution of factor V Leiden. Lancet. 1995 Oct 28;346(8983):1133–1134. doi: 10.1016/s0140-6736(95)91803-5. [DOI] [PubMed] [Google Scholar]
  24. Ridker P. M., Hennekens C. H., Lindpaintner K., Stampfer M. J., Eisenberg P. R., Miletich J. P. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995 Apr 6;332(14):912–917. doi: 10.1056/NEJM199504063321403. [DOI] [PubMed] [Google Scholar]
  25. Rosendaal F. R., Koster T., Vandenbroucke J. P., Reitsma P. H. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance) Blood. 1995 Mar 15;85(6):1504–1508. [PubMed] [Google Scholar]
  26. Svensson P. J., Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994 Feb 24;330(8):517–522. doi: 10.1056/NEJM199402243300801. [DOI] [PubMed] [Google Scholar]
  27. Tabernero M. D., Tomas J. F., Alberca I., Orfao A., Lopez Borrasca A., Vicente V. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol. 1991 Apr;36(4):249–254. doi: 10.1002/ajh.2830360405. [DOI] [PubMed] [Google Scholar]
  28. Trossaërt M., Conard J., Horellou M. H., Elalamy I., Samama M. M. The modified APC resistance test in the presence of factor V deficient plasma can be used in patients without oral anticoagulant. Thromb Haemost. 1996 Mar;75(3):521–522. [PubMed] [Google Scholar]
  29. Voorberg J., Roelse J., Koopman R., Büller H., Berends F., ten Cate J. W., Mertens K., van Mourik J. A. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet. 1994 Jun 18;343(8912):1535–1536. doi: 10.1016/s0140-6736(94)92939-4. [DOI] [PubMed] [Google Scholar]
  30. Williamson T. H., Rumley A., Lowe G. D. Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study. Br J Ophthalmol. 1996 Mar;80(3):203–208. doi: 10.1136/bjo.80.3.203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Zöller B., Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet. 1994 Jun 18;343(8912):1536–1538. doi: 10.1016/s0140-6736(94)92940-8. [DOI] [PubMed] [Google Scholar]
  32. Zöller B., Svensson P. J., He X., Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest. 1994 Dec;94(6):2521–2524. doi: 10.1172/JCI117623. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. van Bockxmeer F. M., Baker R. I., Taylor R. R. Premature ischaemic heart disease and the gene for coagulation factor V. Nat Med. 1995 Mar;1(3):185–185. doi: 10.1038/nm0395-185. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES